NCT02902588 (NM-BBBP) is a NA clinical trial of ICG-PULSION in Blood-Brain Barrier Permeability, sponsored by Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences.

What drugs are being tested in NCT02902588?

Interventions in NCT02902588: ICG-PULSION, LiMON, Pulsion Medical Systems, Gadolinium (Gadovist, Bayer, Germany).

What condition does NCT02902588 study?

NCT02902588 studies Blood-Brain Barrier Permeability.

Is NCT02902588 still recruiting?

NCT02902588 is currently terminated. Last updated 18 October 2018.

Last reviewed 2018-10-18 · How we verify

NCT02902588: NM-BBBP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood-brain Barrier Permeability Study in Adults With Meningitis

Terminated NA Last updated 18 October 2018

What this trial tests

NA trial testing ICG-PULSION in Blood-Brain Barrier Permeability in 20 participants. Terminated before completion.

Timeline

1 August 2015

Primary endpoint
31 January 2018

31 January 2018

Quick facts

Lead sponsor	Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	factorial
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	1 August 2015
Primary completion	31 January 2018
Estimated completion	31 January 2018
Sites	1 location across Poland

Drugs / interventions tested

ICG-PULSION
LiMON, Pulsion Medical Systems
Gadolinium (Gadovist, Bayer, Germany)

Conditions studied

Blood-Brain Barrier Permeability — all drugs for Blood-Brain Barrier Permeability →

Sponsor

Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences

Who can join

18 and older, any sex, with Blood-Brain Barrier Permeability. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to confirm the applicability and usefulness of the novel method of assessment of the permeability of the blood-brain barrier and in monitoring of the treatment of patients with meningitis. The proposed technique is based on evaluation of the kinetics of the indocyanine green (ICG) outflow from the brain with the use of near-infrared spectroscopy (NIRS). Usefulness of the NIRS-based method will be analyzed in relation to the reference method, which is contrast-enhanced magnetic resonance imaging (MRI).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.
Teleanu RI, Preda MD, Niculescu AG, Vladâcenco O, et al · · 2022 · cited 122× · PMID 35631573 · DOI 10.3390/pharmaceutics14050987

Verify or expand the search:

Other Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences trials

Trials by the same sponsor.

NCT03640741 — Changes in Cerebral Oxygenation Studies During Laparoscopy Procedure · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02902588 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences
Last refreshed: 18 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02902588.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing